Zymeworks stock gains as Theravance deal and valuation draw investor focus

Published on 09/18/2026 at 15:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zymeworks stock closed at USD 27.16 on September 17, 2026, valuing the company at about USD 1.94 billion as investors watch its Theravance acquisition plan. The stock trades near a GF Value estimate of USD 26.41, implying a small valuation premium.

ZYME, US98985W1080, Illustration mit AI erstellt.

Zymeworks Inc. stock (ISIN US98985W1080) traded at USD 27.16 on September 17, 2026 on its primary listing in the United States, giving the biopharmaceutical company a market capitalization of about USD 1.94 billion as investors assess its pending acquisition of Theravance Biopharma.

Theravance acquisition shapes Zymeworks strategy

According to Investing.com on September 17, 2026, Theravance Biopharma Inc. has agreed to be acquired by Zymeworks Inc. in a cash-and-contingent value right transaction valued at USD 929 million.

Per the same report, Theravance shareholders are set to receive USD 17.00 per share in cash plus a contingent value right that entitles them to 80 percent of net proceeds from any future license, divestiture or monetization of the drug candidate ampreloxetine over a ten year period, highlighting Zymeworks focus on expanding its respiratory and immunology pipeline through external innovation.

Stock trades near fair value metrics

On September 17, 2026, Zymeworks stock changed hands at USD 27.16, with an intraday high of USD 27.78 and a low of USD 26.25 in Nasdaq trading, and this price was about 3.5 percent above the session low and 2.2 percent below the session high based on data from a US retail brokerage portal that also reported the market capitalization at approximately USD 1.94 billion as of that trading day.

A valuation overview from GuruFocus dated September 17, 2026 cites a GF Value estimate of USD 26.41 for Zymeworks and notes that at a contemporaneous price of USD 27.12, the shares were about 2.7 percent above that intrinsic value measure, indicating that the stock is trading at a small premium to that model based valuation.

Analyst rating backdrop and risk considerations

The same GuruFocus article reports that Wolfe Research initiated coverage of Zymeworks with an Outperform rating as of October 3, 2023, and highlights a GF Score of 63 out of 100, which is characterized as a moderate overall performance profile combining profitability, growth, financial strength and valuation factors.

GuruFocus also points out that despite the positive analyst stance, its internal GF Value model currently classifies Zymeworks as modestly overvalued, which means that any setbacks in integrating the Theravance assets or in monetizing ampreloxetine could weigh on the shares if future cash flows fall short of these expectations.

Zymeworks stock price snapshot

Zymeworks stock closed at USD 27.16 on Nasdaq on September 17, 2026, with a market capitalization around USD 1.94 billion based on that closing price, placing the latest price modestly above the GF Value estimate of USD 26.41 but within a narrow band around that reference.